Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Quanterix investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ:QTRX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 12, 2024, after market hours, Quanterix disclosed that it had “identified an error related to the capitalization of labor and overhead costs applied to prior.

The Law Offices of Frank R. Cruz Announces Investigation of Quanterix Corporation (QTRX) on Behalf of Investors

Quanterix Corporation (NASDAQ:QTRX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Vandana Sriram - CFO Masoud Toloue - President and CEO Conference Call Participants Jake Allen - Goldman Sachs Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Puneet Souda - Leerink Partners Thomas DeBourcy - Nephron Research Operator Thank you for standing by. My name is Andrea and I will be your conference operator today.

Quanterix Corporation (QTRX) Q3 2024 Earnings Conference Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need to restate certain prior period financial statements to correct non-cash errors related to those periods. “Quanterix continues to build on our strong momentum, achieving.

Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results. Quanterix will issue a press release regarding third quarter 2024 financial results prior to the conference call on Tuesday, November 12, 2024, after the market closes. The press release will.

Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer's Disease (AD) in a broader range of patients. Recent Alzheimer's Association criteria for diagnosing Alzheimer's recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this app.

New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer's Disease Diagnostic Information

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Un.

Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer's Disease (AD) test development. The kit uses p-Tau 217 antibody technology licensed from Eli Lilly and Company and Quanterix's SP-X platform. In March 2022, Quanterix first announced its ent.

Quanterix Announces Commercialization of p-Tau 217 Test Kit

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 1:50 p.m. ET. The presentation will be available virtually and participants can register here. The presentation will be.

Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference

Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it.  Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection.

Quanterix Corporation: Still Struggling To Gain Traction

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating.

Jeffrey Elliott Appointed to Quanterix's Board of Directors

Quanterix Corporation (QTRX) Q2 2024 Earnings Call Transcript

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.

Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. “Our research business once again delivered strong performance in the second quarter, growing double digits,” said Masoud Toloue, Chief Executive Officer of Quanterix. “Demand for Simoa sensitivity continues, as highlighted by a 35% increase in Accelerator service.

Quanterix Releases Financial Results for the Second Quarter of 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 3:00 p.m., ET. The presentation will be available virtually and participants can register using this link. The presentation will be.

Quanterix Presenting at Canaccord Genuity 44th Annual Growth Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results. Quanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference call on Thursday, August 8, 2024 after the market closes. The press release will be po.

Quanterix To Report Second Quarter 2024 Financial Results

Quanterix (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today presented new data at the Alzheimer's Association International Conference (AAIC), supporting a novel multi-marker approach to test for Alzheimer's disease (AD). For the first time, new data show that applying a combination of AD-relevant biomarkers with p-Tau 217 significantly reduces the intermediate zone of a two-cutoff p-Tau 217 te.

Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer's Disease Detection that is More Effective than Standalone Plasma p-Tau 217

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024. To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix's Simoa® technology, visit www.quanterix.com/simoa-technology. About Quanterix.

Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general.

Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. Quanterix's presentation is scheduled for Wednesday, May 29, 2024, at 11:40 a.m. ET. The fireside chat will be made available to attendees and to the public via webcast. Webcast Information T.

Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024

The consensus price target hints at a 67.7% upside potential for Quanterix (QTRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade

Quanterix Corporation (NASDAQ:QTRX ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Francis Pruell - Investor Relations Masoud Toloue - President and Chief Executive Officer Vandana Sriram - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Genuity Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q1 2024 Earnings Call Conference Call.

Quanterix Corporation (QTRX) Q1 2024 Earnings Call Transcript

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.16 per share a year ago.

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. “Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase,” said Masoud Toloue, Chief Executive Officer of Quanterix. “We've announced the first of several new assays that could re-define the way Tau.

News for Quanterix Stock (QTRX)